Pulsatile polypoidal vessel in polypoidal choroidal vasculopathy is an important characteristic that has not been reported with any other chorioretinal diseases and could assist in understanding the ...

A 71-year-old Indian male patient presented to the retina–vitreous service of our tertiary care hospital with the complaints of progressive decrease in vision in the right eye over the past 6 months.

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Treatment with Beovu resulted in visual acuity letter gains among patients with age-related ...

Ranibizumab, in combination with prompt verteporfin photodynamic therapy, is more effective in treating polypoidal choroidal vasculopathy compared with ranibizumab monotherapy, according to a study ...

Aflibercept 8 mg administered every 12 or 16 weeks demonstrated comparable improvements in best-corrected visual acuity and central subfield retinal thickness as 2-mg dose every 8 weeks in patients ...

Credit: Getty Images. Brolucizumab demonstrated superior anatomic results and maintained best corrected visual acuity (BCVA) in patients with polypoidal choroidal vasculopathy (PCV) at week 96 of the ...

HealthDay News — Combination therapy consisting of ranibizumab plus verteporfin photodynamic therapy (vPDT) is superior to ranibizumab monotherapy for treatment of eyes with polypoidal choroidal ...

MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and ...